Inventor · disambiguated record
Michael Allen Flynn
Also filed as: Flynn Michael Allen
6 granted patents·48 citations·filing 2017–2022
84Inventor score
Files withAERPIO THERAPEUTICS LLC2EYEPOINT PHARMACEUTICALS INC2AERPIO PHARMACEUTICALS INC1AERPIO THERAPEUTICS INC1
Top patents by PatentIndex Score
6 records- 0196US11180551B2Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)EYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Nov 23, 2021·6 cites·34 claims
- 0295US11136389B2Humanized monoclonal antibodies that target VE-PTP (HPTP-β)AERPIO PHARMACEUTICALS INC·Filed 2020·Granted Oct 5, 2021·5 cites·33 claims
- 0395US10253094B2Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditionsAERPIO THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·13 cites·45 claims
- 0494US10604569B2Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-β/VE-PTP)AERPIO THERAPEUTICS LLC·Filed 2018·Granted Mar 31, 2020·12 cites·36 claims
- 0594US10597452B2Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)AERPIO THERAPEUTICS LLC·Filed 2018·Granted Mar 24, 2020·11 cites·46 claims
- 0692US12145986B2Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)EYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Nov 19, 2024·1 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →